VVOS

Rating neutralAI Memo

Vivos Therapeutics

As of 2026-09-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings growth needs conversion into cash-flow improvement • 2026-12-02

Base target: $0 / p=50% prob

Biggest risk

The company remains highly financing-sensitive: losses and operating cash burn are substantial, cash is limited, product revenue declined during the strategic pivot, and Nasdaq equity-compliance risk creates dilution or delisting downside.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Revenue growth, improved gross margin, SCN service expansion, higher capacity, and potential recurring programs could support a rerating if management reaches positive cash flow by late 2026 or early 2027.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Liquidity, dilution, and Nasdaq compliance remain the nearest stock-moving variables
SCN referral growth and expanded production capacity could support recurring revenue
Florida and Arizona cardiology partnerships may add a later growth leg

BearKey bullets

Dependence on external financing, with dilution and potential listing consequences.
Execution risk in converting SCN referrals, new programs, and expanded capacity into sustainable cash flow.
Limited cash relative to operating cash burn and accumulated losses.

WatchKey bullets

Q2 earnings growth needs conversion into cash-flow improvement

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +94% / -56%

Scenario probabilities

Bull Target: $0 (p=25%)Base Target: $0 (p=50%)Bear Target: $0 (p=25%)

Commentary

News flow is sparse and primarily earnings-summary or company-event driven. The post-Q2 narrative is directionally positive on revenue and gross margin, but cash burn, financing dependence, listing risk, and unavailable analyst-revision data keep this a cautious monitoring setup. Social, options, short-interest, and employee-sentiment data are unavailable in the packet.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Liquidity, dilution, and Nasdaq compliance remain the nearest stock-moving variables
SCN referral growth and expanded production capacity could support recurring revenue
Florida and Arizona cardiology partnerships may add a later growth leg

Scenarios

Bull Target (Scenario probability)

$0 / p=25% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-02
Q2 earnings growth needs conversion into cash-flow improvement
The stored Q2 conference-call context confirms management reviewed results and plans for the rest of 2026. The packet reports Q2 revenue of $5.2 million, up 35% year over year, and gross margin of 57%, but also a $5.5 million net loss, $1.8 million of cash, and $9.2 million of H1 operating cash use. This is a positive operating checkpoint but not yet a de-risked turnaround [#EARNINGS-TRANSCRIPT-2026Q2] [#PR-EARNINGS-2026-08-18].
Prob 60.00% • Move 25.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Liquidity, dilution, and Nasdaq compliance remain the nearest stock-moving variables
2026-12-02
The latest filing cycle is the key monitoring point for liquidity and listing risk. The packet reports continued external-financing dependence, noncompliance with Nasdaq's minimum stockholders' equity requirement, and significant cash burn; the latest 10-Q and subsequent 8-K should be read as formal disclosure checkpoints rather than evidence of a confirmed financing resolution [#SEC-10Q-2026-08-14] [#8-K-2026-08-21].
Prob 70% • Move -25% • Priced-in 70%

Long-term Catalysts

Months to a year

SCN referral growth and expanded production capacity could support recurring revenue
2027-09-03
The packet's stored earnings summary reports a 3-4x increase in referrals from Sleep Center of Nevada patient-volume growth, more than doubled Henderson production capacity, and new CPAP, insomnia/EEG, and sleep-testing initiatives. These remain execution-dependent and require follow-through in revenue, margins, and cash flow [#PR-EARNINGS-2026-08-18].
Prob 35% • Move 55% • Priced-in 25%
Florida and Arizona cardiology partnerships may add a later growth leg
2027-09-03
The stored Q2 earnings summary reports expected capital expenditures of $800,000-$1 million per partnership and revenue potential beginning in Q1 or Q2 2027. Given current liquidity constraints, funding and execution are material gating factors [#PR-EARNINGS-2026-08-18].
Prob 25% • Move 40% • Priced-in 10%

Risks

Dependence on external financing, with dilution and potential listing consequences.
Execution risk in converting SCN referrals, new programs, and expanded capacity into sustainable cash flow.
Limited cash relative to operating cash burn and accumulated losses.
Loose peer set and very limited analyst coverage reduce valuation confidence.
Noncompliance with Nasdaq's minimum stockholders' equity requirement.
Product-revenue decline as the company pivots toward sleep-center services.

Peers

Symbol	Summary
AMIX	Same-sector microcap candidate; useful mainly for framing microcap commercialization and financing risk, not as a close product comp.
LUCY	Same-sector microcap candidate with loose operating overlap; better as a risk-profile reference than a direct sleep-apnea-treatment peer.
POM	Similarly sized same-sector candidate; provides limited valuation context because product and business-model comparability are weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

AMIX

Same-sector microcap candidate; useful mainly for framing microcap commercialization and financing risk, not as a close product comp.

LUCY

Same-sector microcap candidate with loose operating overlap; better as a risk-profile reference than a direct sleep-apnea-treatment peer.

POM

Similarly sized same-sector candidate; provides limited valuation context because product and business-model comparability are weak.